UCB departs industry trade group BIO, following Pfizer’s exit late last year

Brus­sels-based bio­phar­ma com­pa­ny UCB con­firmed Thurs­day that it de­cid­ed not to re­new its mem­ber­ship in the in­dus­try group BIO in 2024, the sec­ond high-pro­file ex­it from the or­ga­ni­za­tion in re­cent months.

“We rou­tine­ly eval­u­ate our en­gage­ment across trade as­so­ci­a­tions and have de­cid­ed not to re­new our mem­ber­ship with the Biotech­nol­o­gy In­no­va­tion Or­ga­ni­za­tion (BIO) for 2024,” a UCB spokesper­son said via email. “We will re­main mem­bers of the Phar­ma­ceu­ti­cal Re­search and Man­u­fac­tur­ers As­so­ci­a­tion of Amer­i­ca (PhRMA) and the Na­tion­al Phar­ma­ceu­ti­cal Coun­cil (NPC), among oth­ers.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.